 SOUTH SAN FRANCISCO, Calif., Aug. 03, 2020 GLOBE NEWSWIRE -- Calithera Biosciences, Inc. Nasdaq: CALA, a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the companys board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 30,000 shares of Calitheras common stock, at a per share exercise price of 4.70, the closing trading price on July 31, 2020. One-fourth of the option vests in July 2021, and the balance of the option vests in a series of thirty-six successive equal monthly installments thereafter and was granted pursuant to the Calithera Biosciences, Inc. 2018 Inducement Plan, or Inducement Plan, which was approved by Calitheras board of directors in January 2018 in accordance with Nasdaq Listing Rule 5653c4. The stock option also has a ten year term and are subject to the terms and conditions of the Inducement Plan and the stock option agreement pursuant to which the option was granted. The stock options were granted as an inducement material to the new employees entering into employment with Calithera in accordance with Nasdaq Listing Rule 5635c4.About CalitheraCalithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit Looking StatementsStatements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, anticipate, estimate, intend, poised and similar expressions as well as other words or expressions referencing future events, conditions, or circumstances are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calitheras product candidates, the overall advancement of Calitheras product candidates in clinical trials, the unmet need in the treatment of patients with advanced disease, and Calitheras plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calitheras stock price. Additional information concerning these and other risk factors affecting Calitheras business can be found in Calitheras most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, and other periodic filings with the Securities and Exchange Commission at These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.SOURCE: Calithera Biosciences, Inc. CONTACT:Jennifer McNealey 650-870-1071 